Retatrutide Where To Get: Clinical Access & Biomarker Personalization

Last reviewed: May 28, 2026

Last updated: August 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Important status note: Retatrutide is an investigational drug being developed by Eli Lilly and Company. As of August 2026, it is not FDA-approved for weight loss, diabetes, or any other indication and cannot legally be sold or marketed for human use in the United States. Federal law also does not permit retatrutide to be used in drug compounding. PlexusDx does not sell, distribute, compound, or prescribe retatrutide.

Retatrutide is being studied as a once-weekly medication that activates three hormone receptors involved in metabolic regulation: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Positive Phase 3 topline results have been announced, but the medication remains investigational while its clinical development and regulatory review process continue.

Lilly announced in July 2026 that it plans to submit retatrutide for U.S. FDA approval in the first quarter of 2027. Until an approval occurs, consumers should be cautious of websites, clinics, or sellers claiming to provide prescription, compounded, or “research-grade” retatrutide for personal use.

Where Is Retatrutide Currently Available?

Retatrutide is not currently available as an FDA-approved prescription medication. At this stage of development, legitimate human access is through authorized clinical research involving retatrutide. Eligibility depends on the requirements of each individual study, and many trial sites may not be actively recruiting.

ClinicalTrials.gov lists ongoing Phase 3 studies evaluating retatrutide for obesity and related cardiometabolic conditions. These studies are sponsored by Eli Lilly rather than by the FDA. Registration of a clinical trial with ClinicalTrials.gov does not mean that the FDA has approved the investigational drug.

The FDA specifically states that retatrutide cannot be used in compounding under federal law. Consumers should therefore be skeptical of online pharmacies, peptide sellers, telehealth companies, or clinics advertising “compounded retatrutide,” “generic retatrutide,” or retatrutide labeled for research use but marketed with instructions for human administration.

What Do Retatrutide Clinical Trials Show?

Retatrutide has produced substantial weight reductions in clinical studies, although results from an investigational drug should not be interpreted as evidence of FDA approval or as a guarantee of individual outcomes.

In a peer-reviewed Phase 2 trial published in the New England Journal of Medicine, adults with obesity receiving the 12 mg dose experienced an average body-weight reduction of approximately 24.2% at 48 weeks. Gastrointestinal adverse events were the most commonly reported side effects and were generally mild to moderate. Dose-dependent increases in heart rate were also observed.

In May 2026, Lilly announced topline results from the Phase 3 TRIUMPH-1 trial. Participants receiving 12 mg retatrutide had an average weight reduction of 28.3% at 80 weeks in the efficacy analysis reported by Lilly. Additional Phase 3 trials have also reported substantial average weight reductions in populations with type 2 diabetes and cardiovascular disease.

These newer Phase 3 findings were announced by the manufacturer as topline results. Full interpretation should consider the eventual peer-reviewed publications, regulatory review, study populations, treatment discontinuations, adverse events, and the specific statistical estimands used in each trial.

Retatrutide vs. Tirzepatide and Semaglutide

The three medications differ primarily in the receptors they activate and their regulatory status.

Agent	Receptor Profile	U.S. Regulatory Status	Routine Prescription Access
Semaglutide	GLP-1 receptor agonist	FDA-approved products available for specific indications	Yes, for FDA-approved products with an appropriate prescription
Tirzepatide	GIP + GLP-1 receptor agonist	FDA-approved products available for specific indications	Yes, for FDA-approved products with an appropriate prescription
Retatrutide	GIP + GLP-1 + glucagon receptor agonist	Investigational; not FDA-approved	No; access is limited to authorized clinical research

It is too early to conclude that retatrutide is definitively more effective or safer than tirzepatide or semaglutide based solely on comparisons across separate clinical trials. Different studies enroll different populations and use different protocols, durations, endpoints, and statistical methods.

A Phase 3 study known as TRIUMPH-5 is directly comparing retatrutide with tirzepatide in adults with obesity. As of August 2026, that study is active but its primary completion is expected later in 2026, so definitive head-to-head results are not yet available.

Can Retatrutide Be Compounded?

No. The FDA states that retatrutide cannot be used in compounding under federal law. It is not a component of an FDA-approved drug and has not been established by FDA as eligible for use as a bulk drug substance for compounding.

This is different from simply saying that a compounded medication is “not FDA-approved.” FDA has specifically identified retatrutide as a substance that cannot currently be used in compounding. Products advertised online as compounded retatrutide should not be assumed to be legal, authentic, sterile, correctly dosed, or suitable for human use.

What About Compounded Semaglutide or Tirzepatide?

Semaglutide and tirzepatide are different because FDA-approved versions of these active ingredients exist. However, compounded versions themselves are not FDA-approved.

The FDA has determined that the national shortages of semaglutide injection and tirzepatide injection have been resolved, and the temporary shortage-related enforcement discretion periods that previously allowed broader compounding have ended. Federal law generally restricts pharmacies from routinely compounding products that are essentially copies of commercially available FDA-approved drugs.

Compounding may still be appropriate in certain patient-specific circumstances when the requirements of federal and state law are satisfied. Whether a compounded formulation is appropriate for a particular patient is a determination involving the licensed prescriber and dispensing pharmacy.

What Role Can Genetics and Biomarkers Play?

Genetics and metabolic biomarkers can provide useful background information about obesity biology and individual metabolic health, but they should not currently be used to claim that someone is a good candidate for retatrutide or to predict how much weight that person will lose on retatrutide.

Variants in genes such as GIPR, FTO, and MC4R have been studied in relation to metabolic traits, body-weight regulation, and related biological pathways. However, these associations are not validated companion diagnostics for retatrutide, and they do not establish which GLP-1, GIP, or glucagon-based medication a patient should receive.

The PlexusDx Precision Peptide Genetic Test provides pathway-level genetic information that can be considered alongside broader health information. It does not diagnose eligibility for retatrutide, predict an individual's response to retatrutide, or replace evaluation by a qualified healthcare provider.

What Is Known About Retatrutide Safety?

Because retatrutide remains investigational, it does not yet have an FDA-approved prescribing label establishing its final indications, dosing instructions, warnings, precautions, or contraindications.

In the published Phase 2 obesity trial, gastrointestinal events such as nausea, diarrhea, vomiting, and constipation were among the most commonly reported adverse effects and were generally mild to moderate. Researchers also observed dose-dependent increases in heart rate that peaked during treatment and later declined.

Phase 3 trials continue to evaluate retatrutide's safety across larger and more diverse patient populations. Clinical trial protocols include eligibility and exclusion criteria intended to protect participants, but those study criteria should not be presented as an FDA-approved list of contraindications for retatrutide.

How PlexusDx Supports Weight-Management Care

PlexusDx does not sell, prescribe, distribute, or compound retatrutide. Patients interested in weight-management treatment can instead complete a PlexusDx intake for evaluation by a licensed provider and discuss currently available treatment options.

Depending on the patient's clinical circumstances, provider judgment, pharmacy requirements, and applicable law, available options may include FDA-approved medications or patient-specific compounded formulations when legally appropriate. Compounded medications are not FDA-approved and should not be described as equivalent to FDA-approved products.

Patients should discuss the benefits, risks, alternatives, expected outcomes, and regulatory status of any medication with their healthcare provider before beginning treatment.

Frequently Asked Questions

Is retatrutide FDA-approved?

No. As of August 2026, retatrutide remains investigational and has not been approved by the FDA for obesity, weight management, diabetes, or any other indication. Lilly has stated that it plans to submit the drug for U.S. FDA approval in the first quarter of 2027.

Where can I get retatrutide?

Retatrutide is not currently available as a routine prescription medication. Legitimate human access is limited to authorized clinical research involving retatrutide. ClinicalTrials.gov can be used to identify registered studies and determine whether any locations are recruiting eligible participants.

Can a 503A pharmacy compound retatrutide?

No. FDA states that retatrutide cannot currently be used in compounding under federal law. Consumers should be cautious of companies advertising compounded, generic, or research-grade retatrutide for personal use.

Can I get retatrutide from PlexusDx?

No. PlexusDx does not sell, distribute, compound, or prescribe retatrutide. PlexusDx offers access to licensed providers who can evaluate patients for currently available weight-management options.

How much weight have people lost with retatrutide in clinical trials?

Results vary by dose, study population, duration, and analysis. In the published Phase 2 obesity trial, participants receiving 12 mg lost an average of approximately 24.2% of their starting body weight at 48 weeks. Lilly later reported a 28.3% average reduction at 80 weeks with 12 mg in its Phase 3 TRIUMPH-1 topline analysis. Individual results cannot be predicted from these averages.

Is retatrutide better than tirzepatide?

That has not yet been established by completed head-to-head Phase 3 evidence. Retatrutide and tirzepatide have produced substantial weight loss in separate clinical programs, but cross-trial comparisons can be misleading. The ongoing TRIUMPH-5 study is directly comparing the two medications.

Is retatrutide the same as tirzepatide?

No. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1, and glucagon receptors. Tirzepatide is available in FDA-approved medications, while retatrutide remains investigational.

Can genetic testing tell me whether retatrutide will work for me?

No validated genetic test currently establishes an individual's eligibility for retatrutide or predicts how much weight that person would lose on the drug. Genetic testing can provide broader information about metabolic pathways and inherited traits, but medication decisions require clinical evaluation.

What are the main side effects seen with retatrutide?

Gastrointestinal effects have been among the most commonly reported adverse events in retatrutide trials. Dose-dependent increases in heart rate were also reported in the Phase 2 obesity study. The drug's complete safety profile remains under investigation.

What currently available treatments can I discuss with a provider?

FDA-approved weight-management medications include therapies based on semaglutide and tirzepatide, among other options. The appropriate treatment depends on an individual's medical history, treatment goals, contraindications, risks, access, and provider assessment.

Related Reading

• Retatrutide Alternatives
• Online Retatrutide
• Zepbound Vs Retatrutide
• Cheapest Retatrutide

Medical and Editorial Standards

Medical review process: This article is intended to be reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, manufacturer-reported clinical trial results when clearly identified as such, and public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized wellness services, and access to provider-directed weight-management programs. PlexusDx does not sell, prescribe, distribute, or compound retatrutide.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, laboratory testing, or health-related care.